Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Jun 2

PMID 34062771

Citations 16

Authors

Saed Abbasi

Satoshi Uchida

Affiliations

Soon will be listed here.

Abstract

Subunit vaccines based on antigen-encoding nucleic acids have shown great promise for antigen-specific immunization against cancer and infectious diseases. Vaccines require immunostimulatory adjuvants to activate the innate immune system and trigger specific adaptive immune responses. However, the incorporation of immunoadjuvants into nonviral nucleic acid delivery systems often results in fairly complex structures that are difficult to mass-produce and characterize. In recent years, minimalist approaches have emerged to reduce the number of components used in vaccines. In these approaches, delivery materials, such as lipids and polymers, and/or pDNA/mRNA are designed to simultaneously possess several functionalities of immunostimulatory adjuvants. Such multifunctional immunoadjuvants encode antigens, encapsulate nucleic acids, and control their pharmacokinetic or cellular fate. Herein, we review a diverse class of multifunctional immunoadjuvants in nucleic acid subunit vaccines and provide a detailed description of their mechanisms of adjuvanticity and induction of specific immune responses.

Citing Articles

CXCL13 promotes broad immune responses induced by circular RNA vaccines.

Wan J, Wang C, Wang Z, Wang L, Wang H, Zhou M Proc Natl Acad Sci U S A. 2024; 121(44):e2406434121.

PMID: 39436660 PMC: 11536096. DOI: 10.1073/pnas.2406434121.

Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity.

Abbasi S, Matsui-Masai M, Yasui F, Hayashi A, Tockary T, Mochida Y Mol Ther. 2024; 32(5):1266-1283.

PMID: 38569556 PMC: 11081875. DOI: 10.1016/j.ymthe.2024.03.022.

mRNA vaccine designs for optimal adjuvanticity and delivery.

Mochida Y, Uchida S RNA Biol. 2024; 21(1):1-27.

PMID: 38528828 PMC: 10968337. DOI: 10.1080/15476286.2024.2333123.

Transcriptional Targeting of Dendritic Cells Using an Optimized Human Gene Promoter.

Zeyn Y, Hobernik D, Wilk U, Pohmerer J, Hieber C, Medina-Montano C Int J Mol Sci. 2023; 24(23).

PMID: 38069260 PMC: 10706967. DOI: 10.3390/ijms242316938.

Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment.

Tockary T, Abbasi S, Matsui-Masai M, Hayashi A, Yoshinaga N, Boonstra E Proc Natl Acad Sci U S A. 2023; 120(29):e2214320120.

PMID: 37428918 PMC: 10629565. DOI: 10.1073/pnas.2214320120.

References

Beutler B, Rietschel E . Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol. 2003; 3(2):169-76. DOI: 10.1038/nri1004. View

Uekama K, Hirayama F, Irie T . Cyclodextrin Drug Carrier Systems. Chem Rev. 2002; 98(5):2045-2076. DOI: 10.1021/cr970025p. View

Lungwitz U, Breunig M, Blunk T, Gopferich A . Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005; 60(2):247-66. DOI: 10.1016/j.ejpb.2004.11.011. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Lim J, Na W, Kim H, Yeom M, Park G, Kang A . Cationic Poly(Amino Acid) Vaccine Adjuvant for Promoting Both Cell-Mediated and Humoral Immunity Against Influenza Virus. Adv Healthc Mater. 2018; 8(2):e1800953. DOI: 10.1002/adhm.201800953. View

Lachelt U, Wagner E . Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond). Chem Rev. 2015; 115(19):11043-78. DOI: 10.1021/cr5006793. View

Abdelmegeed H, Nakamura T, Harashima H . In Vivo Inverse Correlation in the Activation of Natural Killer T Cells Through Dual-Signal Stimulation via a Combination of α-Galactosylceramide-Loaded Liposomes and Interleukin-12. J Pharm Sci. 2016; 105(1):250-6. DOI: 10.1016/j.xphs.2015.10.009. View

Chen H, Li P, Yin Y, Cai X, Huang Z, Chen J . The promotion of type 1 T helper cell responses to cationic polymers in vivo via toll-like receptor-4 mediated IL-12 secretion. Biomaterials. 2010; 31(32):8172-80. DOI: 10.1016/j.biomaterials.2010.07.056. View

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

10.

Kallen K, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A . A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum Vaccin Immunother. 2013; 9(10):2263-76. PMC: 3906413. DOI: 10.4161/hv.25181. View

11.

Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A . Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984; 308(5958):457-60. DOI: 10.1038/308457a0. View

12.

Mamo T, Poland G . Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering. Vaccine. 2012; 30(47):6609-11. DOI: 10.1016/j.vaccine.2012.08.023. View

13.

Chilton P, Hadel D, To T, Mitchell T, Darveau R . Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria. Infect Immun. 2013; 81(9):3317-25. PMC: 3754217. DOI: 10.1128/IAI.01150-12. View

14.

Dupuis M, MacKichan M, Singh M, Doe B, OHagan D, Ulmer J . Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 2001; 7(24):2105-12. DOI: 10.1038/sj.gt.3301347. View

15.

Gandhapudi S, Ward M, Bush J, Bedu-Addo F, Conn G, Woodward J . Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. J Immunol. 2019; 202(12):3524-3536. PMC: 9347971. DOI: 10.4049/jimmunol.1801634. View

16.

Alving C, Rao M, Steers N, Matyas G, Mayorov A . Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines. 2012; 11(6):733-44. DOI: 10.1586/erv.12.35. View

17.

Lavertu M, Methot S, Tran-Khanh N, Buschmann M . High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials. 2006; 27(27):4815-24. DOI: 10.1016/j.biomaterials.2006.04.029. View

18.

Conniot J, Scomparin A, Peres C, Yeini E, Pozzi S, Matos A . Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol. 2019; 14(9):891-901. DOI: 10.1038/s41565-019-0512-0. View

19.

Tiyaboonchai W, Woiszwillo J, Middaugh C . Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles. Eur J Pharm Sci. 2003; 19(4):191-202. DOI: 10.1016/s0928-0987(03)00102-7. View

20.

Ramasamy T, Munusamy S, Ruttala H, Kim J . Smart Nanocarriers for the Delivery of Nucleic Acid-Based Therapeutics: A Comprehensive Review. Biotechnol J. 2020; 16(2):e1900408. DOI: 10.1002/biot.201900408. View